{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:05Z","timestamp":1780549505886,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.7759\/cureus.110204","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:23:50Z","timestamp":1780547030000},"source":"Crossref","is-referenced-by-count":0,"title":["Verification of Budesonide\/Glycopyrronium\/Formoterol (BGF) Triple Therapy in the Department of Cardiology: A Pilot Study"],"prefix":"10.7759","author":[{"given":"Takahiro","family":"Kamihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuya","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00049-2","article-title":"GETting to know the many causes and faces of COPD","volume":"10","author":"Lee H","year":"2022","unstructured":"Lee H, Sin DD. GETting to know the many causes and faces of COPD. Lancet Respir Med. 2022, 10:426-8. 10.1016\/s2213-2600(22)00049-2","journal-title":"Lancet Respir Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(25)00432-1","article-title":"GOLD COPD report: 2026 update","volume":"14","author":"Venkatesan P","year":"2025","unstructured":"Venkatesan P. GOLD COPD report: 2026 update. Lancet respir med. 2025, 14:14-15. 10.1016\/s2213-2600(25)00432-1","journal-title":"Lancet respir med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe KF","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al.. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020, 383:35-48. 10.1056\/NEJMoa1916046","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(18)30327-8","article-title":"Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial","volume":"6","author":"Ferguson GT","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al.. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018, 6:747-58. 10.1016\/s2213-2600(18)30327-8","journal-title":"Lancet Respir Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson DA","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al.. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018, 378:1671-80. 10.1056\/NEJMoa1713901","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2025.01.001","article-title":"The intersection of chronic obstructive pulmonary disease and cardiovascular disease: recent insights in a challenging area","volume":"7","author":"Heffernan M","year":"2025","unstructured":"Heffernan M, Rutherford S. The intersection of chronic obstructive pulmonary disease and cardiovascular disease: recent insights in a challenging area. CJC Open. 2025, 7:493-507. 10.1016\/j.cjco.2025.01.001","journal-title":"CJC Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfn013","article-title":"Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology","volume":"11","author":"Hawkins NM","year":"2009","unstructured":"Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009, 11:130-9. 10.1093\/eurjhf\/hfn013","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.08.046","article-title":"Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure","volume":"49","author":"Le Jemtel TH","year":"2007","unstructured":"Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007, 49:171-80. 10.1016\/j.jacc.2006.08.046","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.02.001","article-title":"Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"6","author":"Canepa M","year":"2018","unstructured":"Canepa M, Fonseca C, Chioncel O, et al.. Performance of prognostic risk scores in chronic heart failure patients enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. JACC Heart Fail. 2018, 6:452-62. 10.1016\/j.jchf.2018.02.001","journal-title":"JACC Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda Y","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013, 48:452-8. 10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-1955","article-title":"The triple therapy for chronic obstructive pulmonary disease increases the risk of pneumonias compared to the dual-bronchodilator therapy","volume":"13","author":"Watanabe K","year":"2021","unstructured":"Watanabe K, Horita N, Kaneko T. The triple therapy for chronic obstructive pulmonary disease increases the risk of pneumonias compared to the dual-bronchodilator therapy. J Thorac Dis. 2021, 13:6099-101. 10.21037\/jtd-20-1955","journal-title":"J Thorac Dis"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1002\/joa3.70314","article-title":"Regional volume of atrial fibrillation catheter ablation is not associated with increased per capita medical costs","volume":"42","author":"Kamihara T","year":"2026","unstructured":"Kamihara T, Kaneko S, Omura T, Shimizu A. Regional volume of atrial fibrillation catheter ablation is not associated with increased per capita medical costs. Journal of Arrhythmia. 2026, 42:70314.","journal-title":"Journal of Arrhythmia"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.07.1651","article-title":"5-year US COPD exacerbation costs extrapolated from the ethos study","volume":"160","author":"Treharne C","year":"2021","unstructured":"Treharne C, Brighton N, Strange C, et al..  5-year US COPD exacerbation costs extrapolated from the ethos study. Chest. 2021, 160:A1838-A1839.","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201711-901ED","article-title":"The \"obesity paradox\" in chronic obstructive pulmonary disease: can it be resolved?","volume":"15","author":"Iyer AS","year":"2018","unstructured":"Iyer AS, Dransfield MT. The \"obesity paradox\" in chronic obstructive pulmonary disease: can it be resolved?. Ann Am Thorac Soc. 2018, 15:158-9. 10.1513\/AnnalsATS.201711-901ED","journal-title":"Ann Am Thorac Soc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043892","article-title":"Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis","volume":"7","author":"Cao C","year":"2012","unstructured":"Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012, 7:e43892. 10.1371\/journal.pone.0043892","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25674","article-title":"The obesity paradox in chronic heart disease and chronic obstructive pulmonary disease","volume":"14","author":"Ravindran SG","year":"2022","unstructured":"Ravindran SG, Saha D, Iqbal I, et al.. The obesity paradox in chronic heart disease and chronic obstructive pulmonary disease. Cureus. 2022, 14:e25674. 10.7759\/cureus.25674","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-020-00394-x","article-title":"Is there an obesity paradox in critical illness? Epidemiologic and metabolic considerations","volume":"9","author":"Karampela I","year":"2020","unstructured":"Karampela I, Chrysanthopoulou E, Christodoulatos GS, Dalamaga M. Is there an obesity paradox in critical illness? Epidemiologic and metabolic considerations. Curr Obes Rep. 2020, 9:231-44. 10.1007\/s13679-020-00394-x","journal-title":"Curr Obes Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2012.11.015","article-title":"The impact of body mass index on the development of systemic inflammatory response syndrome and sepsis in patients with polytrauma","volume":"45","author":"Mica L","year":"2014","unstructured":"Mica L, Vomela J, Keel M, Trentz O. The impact of body mass index on the development of systemic inflammatory response syndrome and sepsis in patients with polytrauma. Injury. 2014, 45:253-8. 10.1016\/j.injury.2012.11.015","journal-title":"Injury"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.70042","article-title":"Deciphering the relationship between sarcopenia and aging: a combined text mining and bioinformatics approach","volume":"25","author":"Kamihara T","year":"2025","unstructured":"Kamihara T, Omura T, Shimizu A. Deciphering the relationship between sarcopenia and aging: a combined text mining and bioinformatics approach. Geriatr Gerontol Int. 2025, 25:806-14. 10.1111\/ggi.70042","journal-title":"Geriatr Gerontol Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-25-0248","article-title":"Innovation in atrial fibrillation treatment and the paradox of regional disparity","volume":"8","author":"Kamihara T","year":"2026","unstructured":"Kamihara T, Kaneko S, Omura T, Shimizu A. Innovation in atrial fibrillation treatment and the paradox of regional disparity. Circ Rep. 2026, 8:510-4. 10.1253\/circrep.CR-25-0248","journal-title":"Circ Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-25-0025","article-title":"Regional disparities in atrial fibrillation catheter ablation based on the Japanese National Survey","volume":"7","author":"Kamihara T","year":"2025","unstructured":"Kamihara T, Kaneko S, Omura T, Hirashiki A, Kokubo M, Shimizu A. Regional disparities in atrial fibrillation catheter ablation based on the Japanese National Survey. Circ Rep. 2025, 7:512-20. 10.1253\/circrep.CR-25-0025","journal-title":"Circ Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/498361-verification-of-budesonideglycopyrroniumformoterol-bgf-triple-therapy-in-the-department-of-cardiology-a-pilot-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:23:53Z","timestamp":1780547033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/498361-verification-of-budesonideglycopyrroniumformoterol-bgf-triple-therapy-in-the-department-of-cardiology-a-pilot-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.110204","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}